Keybank National Association OH Acquires 12,268 Shares of Gilead Sciences, Inc. $GILD

Keybank National Association OH boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 127,547 shares of the biopharmaceutical company’s stock after buying an additional 12,268 shares during the period. Keybank National Association OH’s holdings in Gilead Sciences were worth $17,776,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. TSG Advice Partners LLC lifted its holdings in Gilead Sciences by 275.4% in the 1st quarter. TSG Advice Partners LLC now owns 6,145 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 4,508 shares during the last quarter. Capital Asset Advisory Services LLC grew its holdings in Gilead Sciences by 3.5% during the first quarter. Capital Asset Advisory Services LLC now owns 3,800 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 127 shares during the last quarter. Essex Financial Services Inc. raised its position in shares of Gilead Sciences by 1.2% in the first quarter. Essex Financial Services Inc. now owns 7,814 shares of the biopharmaceutical company’s stock valued at $1,089,000 after purchasing an additional 90 shares during the period. CHICAGO TRUST Co NA raised its position in shares of Gilead Sciences by 15.7% in the first quarter. CHICAGO TRUST Co NA now owns 10,951 shares of the biopharmaceutical company’s stock valued at $1,526,000 after purchasing an additional 1,488 shares during the period. Finally, USS Investment Management Ltd lifted its stake in shares of Gilead Sciences by 4.1% in the first quarter. USS Investment Management Ltd now owns 221,598 shares of the biopharmaceutical company’s stock worth $30,882,000 after buying an additional 8,786 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,000 shares of company stock worth $10,824,500. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research report on Tuesday, June 16th. Citigroup upped their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Rothschild & Co Redburn lowered their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $158.41.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $131.27 on Friday. The company’s fifty day simple moving average is $129.44 and its 200-day simple moving average is $134.53. The company has a market cap of $162.98 billion, a price-to-earnings ratio of 17.88 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.